Supraventricular tachycardia
Supraventricular tachycardia is a general name for a fast heart rhythm that starts above a part of the heart's wiring called the bundle of His. MeSH calls it a generic expression for any tachycardia that begins there. A 2002 open-access review says these rhythms are quite common in clinical practice. It describes a group of regular supraventricular tachycardias: rhythms that run in a loop through an extra electrical pathway between the upper and lower chambers (AVRT), rhythms that loop inside the AV node (AVNRT), and atrial tachycardias, a group that the review says includes atrial flutter.
Also called Tachycardia, Supraventricular · SVT
- Condition
- In this atlas
Overview
Technical summary
MeSH D013617 (exact), last updated 2017-06-20; the definition rests on its scope note. The classification rests on one review from 2002 (PMC1564051, CC BY 2.5), which may not match current naming; its success and complication figures were not recorded. The general statement that a tachycardia is a heartbeat faster than normal rests on the MedlinePlus arrhythmia summary. No treatment guidance, frequency figure or trial result is recorded on this page.
Burden
No burden claims are published.
Claims and evidence
No claims are published for this condition yet.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact Evaluated for this: Flecainide
Applies to Recipient not specified Patients with paroxysmal supraventricular tachycardia, paroxysmal atrial fibrillation or flutter, or life-threatening ventricular arrhythmias, as described in the US label of flecainide acetate tablets
Population, setting and follow-up
- Patients described in the indications section of the label: patients without structural heart disease who have paroxysmal supraventricular tachycardias or paroxysmal atrial fibrillation or flutter with disabling symptoms, and patients with documented life-threatening ventricular arrhythmias. The passages read do not state an age range.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of flecainide acetate tablets (Hikma Pharmaceuticals USA Inc., application ANDA076278; the version dated 2024-12-04 in openFDA) describes flecainide as an antiarrhythmic drug. For patients without structural heart disease it lists prevention of paroxysmal supraventricular tachycardias, including atrioventricular nodal reentrant tachycardia, and of paroxysmal atrial fibrillation or flutter, each when associated with disabling symptoms. It also lists prevention of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the physician's judgment are life-threatening. It states that there is no evidence from controlled trials that flecainide acetate favorably affects survival or the incidence of sudden death.Limitations. This claim records what one US generic label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label's indications section also carries usage statements on chronic atrial fibrillation and on where treatment for sustained ventricular tachycardia begins; they are not recorded here. Contraindications, other warnings, interactions, the label's pediatric statement and dosing were not recorded. The brand label (Tambocor) was not read, and openFDA lists other flecainide labels with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Propafenone
Applies to Recipient not specified Patients with paroxysmal atrial fibrillation or flutter, paroxysmal supraventricular tachycardia, or life-threatening ventricular arrhythmias, as described in the US label of propafenone hydrochloride tablets
Population, setting and follow-up
- Patients described in the indications section of the label: patients without structural heart disease who have paroxysmal atrial fibrillation or flutter, or paroxysmal supraventricular tachycardia, with disabling symptoms, and patients with documented life-threatening ventricular arrhythmias. The passages read do not state an age range.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of propafenone hydrochloride tablets (ANI Pharmaceuticals, Inc., application ANDA076550; the version dated 2025-09-12 in openFDA) describes propafenone as an antiarrhythmic. It lists prolonging the time to recurrence of paroxysmal atrial fibrillation or flutter, and of paroxysmal supraventricular tachycardia, each associated with disabling symptoms in patients without structural heart disease, and treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. It states that the effect of propafenone on mortality has not been determined.Limitations. This claim records what one US generic tablet label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also lists usage considerations (for example, that use in permanent atrial fibrillation has not been evaluated); those are the label's statements and are not repeated as advice. Extended-release capsule labels, which state a narrower atrial fibrillation indication, were not read. Contraindications, other warnings, interactions, the label's pediatric statement and dosing were not recorded. openFDA lists other propafenone labels with different dates, and its own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Verapamil
Applies to Recipient not specified People for whom the US label of verapamil hydrochloride tablets lists an indication: angina, atrial flutter or fibrillation, supraventricular tachycardia, hypertension
Population, setting and follow-up
- Patients described in the indications section of the label. The label does not state an age range in the passages read.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of verapamil hydrochloride tablets, in the Actavis Pharma, Inc. version dated 2024-01-30 in openFDA, lists the medicine for angina (angina at rest, including vasospastic and unstable angina, and chronic stable angina); for arrhythmias (control of ventricular rate at rest and during stress, in association with digitalis, in patients with chronic atrial flutter or atrial fibrillation, and prophylaxis of repetitive paroxysmal supraventricular tachycardia); and for the treatment of hypertension, to lower blood pressure.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry trials 13
Record details
- Record id
cardio:supraventricular-tachycardia- Content hash
bc937a04a3ba266ef9604c618a7d5058fcf0491ddbd1fe541a93343b66194b33